^
Association details:
| Biomarker: | ATM deletion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + VE-821 (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
Published date:
04/17/2020
Excerpt:
A549 cells with deletion of ATM were sensitive to ionising radiation and olaparib. Olaparib induced phosphorylation of DNA damage markers and reversible G2 arrest in ATM-deficient cells, while the combination of olaparib and VE-821 induced cell death....Patients with tumours characterised by ATM-deficiency may benefit from treatment with a PARP inhibitor in combination with an ATR inhibitor.
DOI:
10.1038/s41416-019-0565-8
